CD4 and autoimmune disease: In addition, the treatment has decreased the levels of different types of exosomes with a particular interest in the HLA-DRDPDQ exosome, which plays an important role in presenting the MHC class II molecules to CD4+ T cells for rejection of organ transplantation and autoimmune diseases [24,25,26,27,28].